Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy

被引:17
作者
Barlési, F
Doddoli, C
Torre, JP
Giudicelli, R
Fuentes, P
Thomas, P
Astou, P
机构
[1] Hop St Marguerite, Serv Oncol Thorac, Fed Maladies Resp, Fac Med,Assistance Publ Hop Marseille, F-13274 Marseille, France
[2] Hop St Marguerite, Dept Thorac Surg, Fac Med, Assistance Publ Hop Marseille, F-13274 Marseille, France
[3] CHU Timone, Fac Med, Dept Med Informat, Assistance Publ Hop Marseille, F-13005 Marseille, France
关键词
non-small-cell lung cancer; induction therapy; surgery; chemotherapy; downstaging; vascular invasion;
D O I
10.1016/j.ejcts.2005.06.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Induction Therapy (IT) before surgery emerged as a widely used strategy for IIIAN2 and selected IIIB NSCLC patients. However, IT is associated with a possible increase in postoperative complications. Consequently, selection of patients with the best chances to benefit from combined treatment is mandatory. Methods: Study recorded demographics, treatment and outcome of consecutive patients treated with IT plus surgery for IIIAN2 or IIIB NSCLC. Survival was analysed by Kaplan-Meier and prognostic factors were analysed by log-rank and Cox regression. Results: From 1993 to 2003, 155 patients (IIIAN2=95/IIIB=60) were treated. Complete resection was associated with a significant prolonged median survival both for IIIAN2 (20 vs 16 months, P=0.05) and IIIB (20 vs 15 months, P=0.02) patients. A tower risk of death for IIIAN2 patients was independently associated with postoperative mediastinal lymph node clearance (HR=0.45, 95%Cl [0.25-0.81], P=0.009) and absence of postoperative complication (HR=0.54, 95%Cl [0.31-0.93], P=0.02). Absence of blood vessel invasion only was identified as an independent predictor of a lower risk of death (HR=0.27, 95%Cl [0.12-0.59], P=0.01) for stage IIIB patients. Conclusions: Besides similarities as the rote of a complete R0 resection, treatment-related factors influence outcome of IIIAN2 patients white disease-related factors prevail on survival of IIIB patients, in whom the benefit of IT is unclear. (c) 2005 Published by Elsevier B.V.
引用
收藏
页码:629 / 634
页数:6
相关论文
共 26 条
[1]  
ALBAIN K, 2005, J CLIN ONCOL, V23, pA7014
[2]   CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805 [J].
ALBAIN, KS ;
RUSCH, VW ;
CROWLEY, JJ ;
RICE, TW ;
TURRISI, AT ;
WEICK, JK ;
LONCHYNA, VA ;
PRESANT, CA ;
MCKENNA, RJ ;
GANDARA, DR ;
FOSMIRE, H ;
TAYLOR, SA ;
STELZER, KJ ;
BEASLEY, KR ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1880-1892
[3]  
Albain KS, 1999, P AN M AM SOC CLIN, V18, P467
[4]  
[Anonymous], 1999, WHO INT HISTOLOGICAL
[5]  
Barlesi Fabrice, 2003, Interact Cardiovasc Thorac Surg, V2, P558, DOI 10.1016/S1569-9293(03)00138-5
[6]   Pneumonectomy for malignant disease: Factors affecting early morbidity and mortality [J].
Bernard, A ;
Deschamps, C ;
Allen, MS ;
Miller, DL ;
Trastek, VF ;
Jenkins, GD ;
Pairolero, PC .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 121 (06) :1076-1081
[7]   Mediastinal lymph node clearance after docetaxel-cisplatin Neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer:: A multicenter phase II trial [J].
Betticher, DC ;
Schmitz, SFH ;
Tötsch, M ;
Hansen, E ;
Joss, C ;
von Briel, C ;
Schmid, RA ;
Pless, M ;
Habicht, J ;
Roth, AD ;
Spiliopoulos, A ;
Stahel, R ;
Weder, W ;
Stupp, R ;
Egli, F ;
Furrer, M ;
Honegger, H ;
Wernli, M ;
Cerny, T ;
Ris, HB .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) :1752-1759
[8]   Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer [J].
Cerfolio, RJ ;
Bryant, AS ;
Winokur, TS ;
Ohja, B ;
Bartolucci, AA .
ANNALS OF THORACIC SURGERY, 2004, 78 (06) :1903-1909
[9]  
Depierre A, 2003, B CANCER, V90, P151
[10]   Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer [J].
Depierre, A ;
Milleron, B ;
Moro-Sibilot, D ;
Chevret, S ;
Quoix, E ;
Lebeau, B ;
Braun, D ;
Breton, JL ;
Lemarié, E ;
Gouva, S ;
Paillot, N ;
Bréchot, JM ;
Janicot, H ;
Lebas, FX ;
Terrioux, P ;
Clavier, J ;
Foucher, P ;
Monchâtre, M ;
Coëtmeur, D ;
Level, MC ;
Leclerc, P ;
Blanchon, F ;
Rodier, JM ;
Thiberville, L ;
Villeneuve, A ;
Westeel, V ;
Chastang, C .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :247-253